Heron Therapeutics, Inc. /de/
A biotech company that makes drugs for pain after surgery and for nausea and vomiting tied to chemotherapy. Its U.S.-marketed products include ZYNRELEF, a long-acting local anesthetic for postoperative pain, and CINVANTI and SUSTOL, anti-nausea medicines given to chemotherapy patients. Founded in 1983, the company ran for decades as A.P. Pharma before renaming itself Heron Therapeutics in 2014 as part of a fresh strategic direction and a relisting on the Nasdaq.
Granted 54.0K
Granted 258.3K
Granted 72.7K
Granted 71.0K
Granted 136.8K
Granted 54.0K
Granted 91.8K
Granted 54.0K
Granted 54.0K
Granted 54.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rosen David Efraim +1 co-filer10% owner · 1 transaction | +3.3% | 30.05M | — | — | — |
| Morgan AdamDirector · 1 transaction | +0.6% | 8.88M | 54.0K | — | — |
| Collard Craig AChief Executive Officer, Director · 8 transactions | +59.7% | 757.9K | 258.3K | — | — |
| Duarte IraEVP, Chief Financial Officer · 9 transactions | +61.1% | 264.6K | 72.7K | — | — |
| Forbes William PEVP, Chief Development Officer · 8 transactions | +47.1% | 221.6K | 71.0K | — | — |
| Hensley Mark EarlChief Operating Officer · 2 transactions | — | 136.8K | 136.8K | — | — |
| Christian WaageDirector · 1 transaction | -35.9% | 54.0K | 54.0K | — | — |
| Cusack ThomasDirector · 2 transactions | — | 54.0K | 91.8K | — | — |
| Dissanaike SharmilaDirector · 1 transaction | -38.1% | 54.0K | 54.0K | — | — |
| Johnson Craig ADirector · 1 transaction | -35.6% | 54.0K | 54.0K | — | — |
| Kaseta MichaelDirector · 1 transaction | -3.3% | 54.0K | 54.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.